Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Mar;25(3):153-61.
doi: 10.1089/apc.2010.0006. Epub 2011 Feb 16.

Randomized controlled trial of a personalized cellular phone reminder system to enhance adherence to antiretroviral therapy

Affiliations
Randomized Controlled Trial

Randomized controlled trial of a personalized cellular phone reminder system to enhance adherence to antiretroviral therapy

Helene Hardy et al. AIDS Patient Care STDS. 2011 Mar.

Abstract

Adherence to antiretroviral therapy (ART) represents one of the strongest predictors of progression to AIDS, yet it is difficult for most patients to sustain high levels of adherence. This study compares the efficacy of a personalized cell phone reminder system (ARemind) in enhancing adherence to ART versus a beeper. Twenty-three HIV-infected subjects on ART with self-reported adherence less than 85% were randomized to a cellular phone (CP) or beeper (BP). CP subjects received personalized text messages daily; in contrast, BP subjects received a reminder beep at the time of dosing. Interviews were scheduled at weeks 3 and 6. Adherence to ART was measured by self-report (SR, 7-day recall), pill count (PC, past 30 days at baseline, then past 3 weeks), Medication Event Monitoring System (MEMS; cumulatively at 3 and 6 weeks), and via a composite adherence score constructed by combining MEMS, pill count, and self report. A mixed effects model adjusting for baseline adherence was used to compare adherence rates between the intervention groups at 3 and 6 weeks. Nineteen subjects completed all visits, 10 men and 9 females. The mean age was 42.7 ± 6.5 years, 37% of subjects were Caucasian and 89% acquired HIV heterosexually. The average adherence to ART was 79% by SR and 65% by PC at baseline in both arms; over 6 weeks adherence increased and remained significantly higher in the ARemind group using multiple measures of adherence. A larger and longer prospective study is needed to confirm these findings and to better understand optimal reminder messages and user fatigue.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Overview of ARemind 1 System. To begin, a caregiver registers a patient's mobile number, content preference, and dosing schedule in the system (1). At the scheduled time, the scheduler pulls fresh content from third party content providers (2), then generates a text message which is sent to the patient (3). The patient responds to the text message indicating that they have taken their medication (4).
FIG. 2.
FIG. 2.
Composite adherence score (CAS) over time by intervention group. Closed circle: Adjusted composite adherence score (%) for subjects randomized to the beeper arm. Open circle: Adjusted composite adherence score (%) for subjects randomized to the cellular phone arm. Closed square: Baseline adjusted adherence rate calculated via pill count; d: difference in composite adherence score between the beeper arm and cellular phone arm.

References

    1. Nachega JB. Hislop M. Dowdy DW. Chaisson RE. Regensberg L. Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564–573. - PubMed
    1. Gross R. Yip B. Lo Re V, 3rd, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108–1114. - PubMed
    1. Ramadhani HO. Thielman NM. Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among hiv-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45:1492–1498. - PubMed
    1. Paterson DL. Swindells S. Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in subjects with HIV infection. Ann Intern Med. 2000;133:21–30. - PubMed
    1. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:942–944. - PubMed

Publication types

Substances